Interventional radiology

Identification of Alpelisib (BYL 719) as a Potential Treatment for Endometrial Cancers

Retrieved on: 
Tuesday, June 16, 2020
Medicine, RTT, Medical specialties, Clinical medicine, Biopsy, Interventional radiology, Cancer

The study compared Alpelisib activity in 388 patient-derived specimens isolated from surgical biopsies to examine disease-specific activity and found uterine cancers to be significantly more sensitive than other tumor types.

Key Points: 
  • The study compared Alpelisib activity in 388 patient-derived specimens isolated from surgical biopsies to examine disease-specific activity and found uterine cancers to be significantly more sensitive than other tumor types.
  • The EVA/PCD results confirm these alterations to be therapeutic targets for Alpelisib with these PIK3CA-related tumors proving to be the most sensitive.
  • Additional analyses compared the activity of Alpelisib with other classes of drugs and explored novel drug combinations for activity and synergy.
  • Caught early it can be cured with surgery, but the treatment of advanced disease remains an unmet need in contemporary medical oncology.

FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

Retrieved on: 
Tuesday, June 16, 2020
Cardiac arrhythmia, Medicine, Medical specialties, Circulatory system, RTT, Interventional radiology, Surgical oncology, Medical terminology, Radiofrequency ablation, Ventricular tachycardia, Ablation, Tachycardia

Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.

Key Points: 
  • Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
  • In addition, Thermedicals ablation system with degassed saline reduces air bubble volume generated during VT ablation by greater than 98%.
  • In total, there have been 21 patients treated with SERF ablation in Canada, and five treatments also included degassed saline.
  • The Saline Enhanced Radiofrequency (SERF) VT Ablation Early Feasibility Study (EFS) is underway at six centers in the U.S. and Canada.

FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

Retrieved on: 
Tuesday, June 16, 2020
Medical devices, FDA, Health, Hospitals, Surgery, Cardiology, Medicine, Cardiac arrhythmia, RTT, Cardiovascular system, Circulatory system, Interventional radiology, Surgical oncology, Medical terminology, Radiofrequency ablation, Ventricular tachycardia, Ablation, Heart arrhythmia, Montreal Heart Institute, Thermedical

Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.

Key Points: 
  • Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
  • The reason is that Thermedicals SERF ablation using degassed saline can reach abnormal muscle fibers deep in the heart wall where standard ablation cannot reach and where life-threatening arrhythmias are often located.
  • In addition, Thermedicals ablation system with degassed saline reduces air bubble volume generated during VT ablation by greater than 98%.
  • In total, there have been 21 patients treated with SERF ablation in Canada, and five treatments also included degassed saline.

Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

Retrieved on: 
Monday, June 15, 2020
Science, Cardiology, Other Science, Research, Surgery, Health, Medical devices, Other Health, Medical specialties, Angiology, Medicine, Vascular surgery, Endovascular aneurysm repair, Interventional radiology, Evar, Vascular diseases, Polymer, Aneurysm, Ovation

Endologix is committed to replacing Ovation iX with the recently FDA-approved ALTO graft by the end of October 2020.

Key Points: 
  • Endologix is committed to replacing Ovation iX with the recently FDA-approved ALTO graft by the end of October 2020.
  • Ovation iX is differentiated from traditional devices for endovascular aneurysm repair (EVAR) through the use of liquid polymer.
  • In the transition to ALTO, physicians may be considering when to select Ovation iX for their patients given the root cause of polymer leaks.
  • To clarify the decision-making process, Endologix has updated the labelling of the Ovation iX platform with the following warning: Polymer leaks are a unique potential risk of the Ovation iX device platform that have been reported post-market.

Study demonstrates feasibility of hologram technology in liver tumor ablation

Retrieved on: 
Monday, June 15, 2020
Medicine, Medical specialties, Clinical medicine, Hepatology, Microwave ablation, Interventional radiology, Ablation, Liver tumor, Interventional oncology, Irreversible electroporation

In this initial in-human pilot study , the technology was used to deliver a treatment known as percutaneous thermal ablation of solid liver tumors.

Key Points: 
  • In this initial in-human pilot study , the technology was used to deliver a treatment known as percutaneous thermal ablation of solid liver tumors.
  • To apply this technology, interventional radiologists from the Cleveland Clinic use multi-phase CT to record coordinate markers placed on a patient's body.
  • The study included five patients who were selected for microwave ablation of their liver tumors.
  • Post-procedural imaging showed adequate tumor ablation, and nopatients experienced tumor recurrence at the three-month follow-up.

Global Stents Market Analysis and Forecasts - Market Forecast to Grow at a CAGR of 5.21% During 2020-2025

Retrieved on: 
Friday, June 12, 2020
Medical devices, Medical technology, Interventional cardiology, Medicine, Medical equipment, Interventional radiology, Stent, Coronary stent, Drug-eluting stent

The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.

Key Points: 
  • The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.
  • The global stents market is estimated to witness significant growth during the forecast year due to increased incidence of heart-related diseases and huge demand for various diagnosis and treatment methods.
  • The global stents market is analyzed to be dominated by the coronary stents with a share of 58% in 2020.
  • Analyzes the market size and giving the forecast for current and future Stents market during the forecast period 2020-2023.

COVID-19 Impact and Recovery Analysis- Aortic Stent Grafts Market 2020-2024 | Rising Preference for EVAR to Boost Growth | Technavio

Retrieved on: 
Thursday, June 11, 2020
Medical Supplies, Medical devices, Health, Surgery, General Health, Cardiology, Medical specialties, Medicine, Interventional radiology, Angiology, Vascular surgery, Vascular diseases, Endovascular aneurysm repair, Stent, Evar, Aneurysm

View the full release here: https://www.businesswire.com/news/home/20200610005672/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200610005672/en/
    Technavio has announced its latest market research report titled Global Aortic Stent Grafts Market 2020-2024 (Photo: Business Wire).
  • Market estimates include pre- and post-COVID-19 impact on the Aortic Stent Grafts Market Download free sample report
    The market is concentrated, and the degree of concentration will accelerate during the forecast period.
  • Rising preference for Endovascular Aneurysm Repair (EVAR) procedures has been instrumental in driving the growth of the market.
  • https://www.technavio.com/report/report/aortic-stent-grafts-market-indus...
    Aortic Stent Grafts Market 2020-2024: Segmentation
    Aortic Stent Grafts Market is segmented as below:

The Global Contrast Injector Market is expected to grow from USD 607.47 Million in 2019 to USD 921.99 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.20%

Retrieved on: 
Wednesday, June 10, 2020
Medical imaging, Interventional radiology, Medicine, Radiology, Interventional cardiology, Injector, Market

On the basis of Application, the Contrast Injector Market is studied across Interventional Cardiology, Interventional Radiology, and Radiology.

Key Points: 
  • On the basis of Application, the Contrast Injector Market is studied across Interventional Cardiology, Interventional Radiology, and Radiology.
  • On the basis of Geography, the Contrast Injector Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Contrast Injector Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Contrast Injector Market?

Reflow Medical Enrolls First Patients in the DEEPER LIMUS Study of the Temporary Spur Stent System

Retrieved on: 
Wednesday, June 10, 2020
Health, Clinical trials, Cardiology, Medical devices, Medical devices, Interventional radiology, Medicine, Stent, Interventional cardiology

Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-RanDomized Pilot Study of the TEmporary Spur StEnt System for the Treatment of Lesions Located in the InfraPoplitEal ARteries Using a LIMUS-base Drug-coated Balloon (DEEPER LIMUS).

Key Points: 
  • Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-RanDomized Pilot Study of the TEmporary Spur StEnt System for the Treatment of Lesions Located in the InfraPoplitEal ARteries Using a LIMUS-base Drug-coated Balloon (DEEPER LIMUS).
  • The OUS single center clinical trial (NCT04162418) is expected to enroll up to 30 participants and last approximately six months.
  • View the full release here: https://www.businesswire.com/news/home/20200610005535/en/
    Temporary Spur Stent System (Investigational use only) (Photo: Business Wire)
    The Temporary Spur Stent System is a novel retrievable stent designed to treat long, diffuse and severely calcified infrapopliteal disease.
  • This new study data will be added to a portfolio of other studies completed or currently enrolling on this groundbreaking medical technology.

Global Stents Market Analysis and Forecasts 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 8, 2020
Medical devices, Health, Medical devices, Medical technology, Interventional cardiology, Medicine, Medical equipment, Interventional radiology, Stent, Coronary stent, Drug-eluting stent

The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.

Key Points: 
  • The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.
  • The global stents market is estimated to witness significant growth during the forecast year due to increased incidence of heart-related diseases and huge demand for various diagnosis and treatment methods.
  • The global stents market is analyzed to be dominated by the coronary stents with a share of 58% in 2020.
  • Analyzes the market size and giving the forecast for current and future Stents market during the forecast period 2020-2023.